<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864054</url>
  </required_header>
  <id_info>
    <org_study_id>ETUS20GPC3AR124</org_study_id>
    <nct_id>NCT04864054</nct_id>
  </id_info>
  <brief_title>ECT204 T-Cell Therapy in Adults With Advanced HCC</brief_title>
  <acronym>ARYA3</acronym>
  <official_title>An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eureka Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eureka Therapeutics Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open-label, dose escalation, multi-center, Phase I/II clinical trial to&#xD;
      assess the safety of ECT204 T-cell therapy and determine the RP2D in adult subjects (≥ 18&#xD;
      years of age) who have GPC3-positive HCC and have failed or not tolerated at least two (2)&#xD;
      different anti-HCC systemic agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate an autologous T-cell therapy for advanced&#xD;
      hepatocellular carcinoma (HCC). ECT204 T cells are autologous T cells genetically modified to&#xD;
      carry a construct capable of mediating cell killing by targeting tumor specific antigens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rates of adverse events (AEs) after infusion of ECT204 T cells</measure>
    <time_frame>28 days</time_frame>
    <description>Safety of ECT204 T cells as assessed by the number of adverse events (AEs) after infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity rates of adverse events (AEs) after infusion of ECT204 T cells</measure>
    <time_frame>28 days</time_frame>
    <description>Safety of ECT204 T cells as assessed by the severity of adverse events (AEs) after infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rates of dose limiting toxicities (DLTs) after infusion of ECT204 T cells</measure>
    <time_frame>28 days</time_frame>
    <description>Tolerability of ECT204 T cells after infusions assessed by committee review of dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The recommended phase 2 dose (RP2D) of ECT204 T cells</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The RP2D will be determined by the study Dose Escalation Committee (DEC) and chosen&#xD;
based on the maximum tolerated dose (MTD) but will not exceed the MTD and the maximum administered dose (MAD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of ECT204 T cells in subjects with advanced HCC by radiographic scans assessed according to RECIST and iRECIST criteria.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Response rate will be assessed by radiographic scans and assessed according to RECIST and iRECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Maximum Concentration (Cmax) of ECT204 T cells in blood after infusion.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Determine the degree of expansion of ECT204 T cells after infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Time of Maximum Concentration (Tmax) of ECT204 T cells in blood after infusion.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Determine the expansion kinetics of ECT204 T cells after infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Area under the curve (AUC) at fixed time intervals (e.g., from Day 0 to Day 28).</measure>
    <time_frame>28 days</time_frame>
    <description>Assess the expansion and persistence of ECT204 T cells after infusion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cancer, Adult</condition>
  <condition>Liver Neoplasm</condition>
  <condition>Metastatic Liver Cancer</condition>
  <arm_group>
    <arm_group_label>ECT204</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A minimum of twelve (12) subjects will be treated to determine the RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ECT204 T cells</intervention_name>
    <description>ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.</description>
    <arm_group_label>ECT204</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed HCC, which is unresectable, recurrent and/or metastatic.&#xD;
&#xD;
          -  GPC3-positive expression in HCC tumor cells by immunohistochemistry (IHC).&#xD;
&#xD;
          -  Must have failed or not tolerated at least two (2) different anti-HCC systemic agents.&#xD;
&#xD;
          -  Life expectancy of at least 4 months per Principal Investigator's opinion.&#xD;
&#xD;
          -  Karnofsky Performance Scale ≥ 70.&#xD;
&#xD;
          -  Measurable disease by RECIST v.1.1. Previously treated lesions are allowed as long as&#xD;
             there is a new confirmed measurable component.&#xD;
&#xD;
          -  Child-Pugh score A6 or better.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant pre-existing illness (e.g., heart failure)&#xD;
&#xD;
          -  Uncontrolled systemic bacterial, fungal, or viral infection&#xD;
&#xD;
          -  Active malignancy other than HCC, with the exception of cholangiocarcinoma (CCA)&#xD;
             without any organ involvement and with an expected survival greater than or equal to 3&#xD;
             years without any treatment (exception: hormone/androgen- deprivation therapy)&#xD;
&#xD;
          -  Active autoimmune disease requiring therapy&#xD;
&#xD;
          -  Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction&#xD;
&#xD;
          -  History of organ transplant&#xD;
&#xD;
          -  Advanced HCC involving greater than half (50%) of the liver&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei Wang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eureka Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen B Cravotto</last_name>
    <phone>510-722-8719</phone>
    <email>karen.cravotto@eurekainc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pei Wang, PhD</last_name>
    <phone>510-654-7045</phone>
    <email>pei.wang@eurekainc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Aceves</last_name>
      <phone>626-218-5114</phone>
      <email>CAceves@coh.org</email>
    </contact>
    <investigator>
      <last_name>Daneng Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas University Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Roesgen</last_name>
      <phone>913-945-8679</phone>
      <email>jroesgen@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Raed Al-Rajabi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma HCC</keyword>
  <keyword>Advanced HCC</keyword>
  <keyword>Late-Stage HCC</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>Liver Neoplasm</keyword>
  <keyword>Metastatic Liver Cancer</keyword>
  <keyword>Metastatic HCC</keyword>
  <keyword>T-cell therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

